27 results about "Antihypertensive medication" patented technology

The invention discloses a synthesis method of a high-purity and high-yield antihypertensive drug, and relates to the technical field of medical chemistry. The method comprises the following steps: taking glycollic acid as an initial raw material, and carrying out acylation to obtain glycollic acid acyl chloride; carrying out Friedel-Crafts reaction on the 2-hydroxyl-5-(2-hydroxyacetyl) benzamide and salicylamide to obtain 2-hydroxyl-5-(2-hydroxyacetyl) benzamide; then, a Dess-Martin oxidizing agent is used for oxidation, and 2-hydroxy-5-(2-oxoacetyl) benzamide is obtained; the preparation method comprises the following steps: taking 2-hydroxyl-5-((4-phenylbutylamine-2-yl)-ethyl) benzamide as a raw material, then carrying out reductive amination on the 2-hydroxyl-5-(4-phenylbutylamine-2-yl)-ethyl) benzamide and 1-methyl-3-phenylpropylamine under the condition that sodium borohydride is taken as a reducing agent to obtain 2-hydroxyl-5-(1-hydroxyl-2-((4-phenylbutylamine-2-yl)-amino) ethyl) benzamide, namely And finally salifying with concentrated hydrochloric acid, crystallizing and separating to obtain the labeolol hydrochloride. The method is novel in route, convenient to operate, high in product total yield, high in purity, capable of effectively avoiding generation of dibromo impurities and suitable for large-scale production.

This invention discloses an octapeptide derived from soybean protein with the function of lowering blood pressure, blood sugar, and cholesterol, as well as its preparation and application, belonging to the field of small molecule peptide technology. The octapeptide sequence is YEGNWGPL, which can be obtained artificially or by targeted enzymatic hydrolysis of soybean protein isolate. Functional verification in a hyperlipidemia model shows that the octapeptide YEGNWGPL has the function of lowering blood lipids; functional verification in a hyperglycemia model shows that the octapeptide YEGNWGPL has the function of lowering blood sugar, with a significantly better effect than the drug metformin; functional verification in a hypertension model shows that the octapeptide YEGNWGPL has the function of lowering blood pressure, with a significantly better effect than the antihypertensive drug captopril; moreover, food-derived bioactive peptides have high biosafety, therefore, they can be applied to the development of related products for lowering blood pressure, blood sugar, and cholesterol or assisting in lowering blood pressure, blood sugar, and cholesterol, with good market prospects and application potential.

This invention belongs to the field of biomedical technology, specifically relating to the application of TLR1 receptor inhibitors in the preparation of products for treating hypertension. Existing drugs used clinically for hypertension have varying mechanisms of action. This study discovers a novel mechanism for treating hypertension: by inhibiting TLR1 receptors in juxtaglomerular cells of the kidney and hepatocytes of the liver, sympathetic nerve excitation-induced renin synthesis and glucocorticoid-induced angiotensinogen synthesis are suppressed, thereby inhibiting angiotensin II levels. This mechanism and method provide a new treatment option for hypertension, particularly neurogenic hypertension, and can also exhibit synergistic effects with existing therapeutic drugs. This invention identifies the TLR1 receptor as a novel target for treating hypertension. Currently, there are no developed and applied hypertension treatment drugs mediated by TLR1 receptors. This invention provides sufficient theoretical and experimental basis for the development of novel antihypertensive drugs.

A heart failure management system for a patient includes a plurality of sensors including at least one implantable pressure sensor positioned within the heart to capture synchronized left and right heart pressure waveforms, transmitted via one or more transmitters to a receiver. Control circuitry receives these waveforms and processes them using a machine learning medication dosage management model, trained on historical left and right heart pressure logs, volume status metrics (e.g., weight, fluid intake, symptoms), and / or ground truth dosage logs for certain heart failure treatment medications, such as a blood pressure reducing medication (e.g., ARNI) and an intravascular volume reducing medication (e.g., Lasix). The model can generate real-time dosage recommendations, systemic blood pressure, and volume load predictions in real-time, enabling precise, data-driven treatment adjustments aligned with clinical guidelines, supporting timely clinical decisions or automated medication dispensing to optimize patient outcomes and reduce hospitalization risks.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for reducing blood pressure and a preparation method thereof. The product provided by the invention is suitable for primary hypertension patients, especially patients who have poor tolerance to chemical antihypertensive drugs and worry about adverse reactions or prefer to traditional Chinese medicine treatment. Patients orally take the traditional Chinese medicine composition according to recommended doses every day, and the effect of reducing blood pressure is achieved through the synergistic effect of all the components in the traditional Chinese medicine composition (for example, the chrysanthemum bud has the effect of clearing heat and calming the liver, the radix puerariae has the effect of clearing and activating the channels and collaterals, the earthworm has the effect of clearing heat and arresting convulsion, the eucommia ulmoides has the effect of tonifying liver and kidney and strengthening muscles and bones, and the radix paeoniae alba has the effect of nourishing blood and liver).

The invention discloses a telmisartan and hydrochlorothiazide compound tablet which is characterized in that the telmisartan and hydrochlorothiazide compound tablet comprises a double-layer tablet A and a double-layer tablet B, and the layer A is prepared from telmisartan lipidosome, a diluent and a lubricant; and the layer B is prepared from hydrochlorothiazide, a diluent, a disintegrating agent, a lubricant and an antioxidant. The telmisartan liposome comprises lipid and telmisartan, the dosage ratio of the lipid to the telmisartan is (0.5-2.3): 1, the lipid comprises phospholipid and cholesterol, and in the lipid, the content of the cholesterol accounts for 20%-60% of the total amount of the lipid. The telmisartan liposome comprises lipid, telmisartan and a PH buffer solution, and the PH of the PH buffer solution is 5-7. According to the telmisartan and hydrochlorothiazide compound tablet prepared by the invention, the telmisartan dissolution is good, and the tablet is safe and stable.

To provide a useful blood pressure elevation suppressant. [Solution] A blood pressure elevation inhibitor containing as an active ingredient one or more compounds selected from the group consisting of saclipin A (a compound represented by the following formula (2)), saclipin B, and derivatives thereof, isolated from an extract of Suizenji Nori. TIFF2026115124000007.tif68169

This invention provides an ACE-inhibiting peptide and its application in health foods and antihypertensive drugs, belonging to the field of ACE-inhibiting peptide technology. The ACE-inhibiting peptide is formed by the sequential condensation of Val-Val-Pro-Pro-Gly-His-His-Pro-Phe, with the amino acid sequence: VVPPGHPF. At the same peptide concentration, the ACE-inhibiting effect is further enhanced when this ACE-inhibiting peptide is mixed with other ACE-inhibiting peptides, and it also has a hypotensive effect on hypertensive mice. The ACE-inhibiting peptide of this invention has a small molecular weight and is easily absorbed, making it a potential natural antihypertensive drug or health food. It also opens up new avenues for the development of black beans and the high-value utilization of processing by-products.

This invention discloses a casein-derived small molecule peptide with antihypertensive effect and its preparation method, belonging to the field of bioactive peptide technology. The preparation method is as follows: S1, mix casein with water and stir until homogeneous; S2, add a complex protease for enzymatic hydrolysis, then add bromelain for further enzymatic hydrolysis to inactivate the enzyme; S3, centrifuge the mixture; S4, heat the separated mixture, add activated carbon for adsorption, then add diatomaceous earth, stir until homogeneous, and filter; S5, further filter through a membrane; S6, concentrate the mixture, sterilize, and dry to obtain the casein-derived small molecule peptide. The casein-derived small molecule peptide of this invention can effectively lower blood pressure by inhibiting ACE activity and blocking the production of angiotensin II. This small molecule peptide significantly increases blood flow activity and angiotensin II content in a hypertensive model zebrafish, exhibiting a dose-dependent effect, achieving the same effect as the antihypertensive drug captopril, and with an efficacy concentration that is half that of the positive control drug.

The application discloses a traditional Chinese medicine formula for treating hypertension and a preparation method thereof, and belongs to the technical field of formula preparation of hypertension and comprises the following raw materials in parts by weight: 5-15 parts of rhubarb, 5-15 parts of dried ginger, 5-15 parts of oyster shell, 5-15 parts of oyster, 5-15 parts of cassia twig, 5-15 parts of white peony root, 5-15 parts of prepared rehmannia root and 5-15 parts of mountain yam. In the application, the core compatibility of Feng Yin decoction, Liuwei Dihuang decoction, Taohong Siwu decoction and Huanglian Jiedu decoction is fused, the five effects of 'calming liver and suppressing yang, nourishing yin and kidney, promoting blood circulation and removing blood stasis, clearing heat and resolving toxin and invigorating spleen and stomach' are considered, the pathogenesis of 'deficiency in origin and excess in superficiality' of hypertension is adjusted as a whole, compared with existing western medicines, the drug has stable and long-acting effect, can effectively reduce blood pressure, can significantly improve dizziness, headache, chest distress and other accompanying symptoms, can reduce the dependence of patients on chemical antihypertensive drugs and side effects such as liver and kidney damage and electrolyte disturbance caused by the chemical antihypertensive drugs, and is especially suitable for long-term taking of middle-aged and old patients and patients with combined basic diseases.

The invention discloses a supramolecular group composite peptide-containing antihypertensive composition, which is composed of raw materials and basic energy substrates, the raw materials comprise composite peptide, phytosterol, taurine and the like, and the basic energy substrates comprise proteins, dietary fibers, fatty acids and / or lipids; the composite peptide is composed of Anbenefit milk polypeptide and balsam pear peptide. According to the present invention, the components of the specific types and the specific amounts are selected and compounded, such that the prepared composition has effects of significant cardiac output reducing and blood vessel diameter increasing, and the partial composition can cooperate with valsartan (antihypertensive drug) to achieve effects of synergistic blood pressure reducing so as to provide effects of auxiliary improvement or prevention of blood pressure reducing. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The application provides a scomber ACE inhibitory peptide as well as a preparation method and application thereof, and relates to the technical field of ACE inhibitory peptides.The scomber ACE inhibitory peptide provided by the application comprises an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.2.Through papain enzymolysis, ultrafiltration, gel chromatography, liquid chromatography-tandem mass spectrometry sequence identification and QSAR modeling, the application improves the working efficiency of ACE inhibitory peptide screening, prepares and screens scomber ACE inhibitory peptides with high angiotensin converting enzyme inhibitory effect, and the scomber ACE inhibitory peptides can be used for developing new antihypertensive drugs, and have a wide application prospect.

This invention discloses a turtle peptide with angiotensin-converting enzyme (ACE) inhibitory activity, its preparation, and its application, belonging to the field of biotechnology. Using turtle as raw material, this invention obtains peptide components with a molecular weight less than 5 kDa through enzymatic hydrolysis and ultrafiltration. Sequencing reveals three peptide sequences with ACE inhibitory activity: AAGPAGGNLN, EAGAQGPPGA, and GARGDK. In vitro activity experiments verified the ACE inhibitory function of the three turtle peptides. The turtle peptide combination prepared by this invention exhibits significant ACE inhibitory activity and can be used to develop functional foods or antihypertensive drugs. Furthermore, the preparation method is environmentally friendly, efficient, and suitable for industrial production.

This invention relates to the field of pharmaceutical analysis technology, specifically to a method for determining the concentration of the antihypertensive drug losartan in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS / MS). The mobile phase of the LC comprises an aqueous formic acid solution and acetonitrile; the elution program of the LC includes: 60-80% acetonitrile by volume in the mobile phase for 0-1.4 min; and a flow rate of 0.6-1 mL / min. This invention provides a highly efficient and accurate method for detecting losartan drug concentration, enabling precise determination of the losartan concentration in plasma and ensuring the accuracy and reliability of the data.

The present invention relates to the pharmaceutical technology. Keratin CF2, methods for producing the same, pharmaceutical compositions containing the same and the use thereof are disclosed, and the present invention particularly relates to keratin CF2, nucleic acid molecules encoding the keratin CF2, expression vectors containing the nucleic acid molecule, host cells containing the expression vector or in which the nucleic acid molecule is incorporated into the genome, methods for producing the keratin CF2, pharmaceutical compositions containing the keratin CF2, and the use of the keratin CF2, nucleic acid molecules, expression vectors, host cells or pharmaceutical compositions in the manufacture of antipyretics, analgesics, antitussives, expectorants, anticonvulsants, antiepileptics, antihypertensives, anti-inflammatorys or antivirals.

The invention provides a method for detecting illegal antihypertensive drug components in antihypertensive functional food, which comprises the following steps: firstly, qualitatively screening three compounds, namely rutin, torasemide and azilsartan, in the functional food by adopting high performance liquid chromatography-ultraviolet spectrum, and then further detecting and analyzing by adopting high performance liquid chromatography-mass spectrometry. The method disclosed by the invention has the characteristics of exclusiveness, sensitivity and rapidness, and provides a reliable means for screening, confirming and supervising rutin, torasemide and azilsartan in antihypertensive functional food through methodology verification; the method is mainly suitable for determining the content of rutin, torasemide and azilsartan in foods such as substitutional tea drinks, tablet candies and the like and functional foods such as capsules, tablets and the like.

The application belongs to the field of biological medicine, and provides application of inosine in preparation of a drug for preventing and / or treating preeclampsia. The pathological state of preeclampsia is simulated by subcutaneous injection of a solution of nitroso-L-arginine methyl ester (125 mg / kg). From the 9th day of pregnancy, inosine is administered by gavage once a day (100 mg / kg), until the end of pregnancy. Compared with drugs such as labetalol, magnesium sulfate and other drugs with single treatment effect, the application proves that oral inosine can not only significantly improve hypertension and proteinuria caused by preeclampsia, repair placental function, promote intrauterine growth and development of the fetus, correct the imbalance of vascular and anti-angiogenic factors, but also reduce the damage to the kidneys and brain of pregnant women induced by preeclampsia, and exhibits a more comprehensive treatment effect, thereby providing a new therapeutic drug for preventing or treating preeclampsia.

The present invention provides a method of treating hypertension in a hypertensive subject, the method comprising administering to the subject an amount of an angiotensin II receptor blocker (ARB), an amount of a thiazine-based or thiazine-like diuretic agent once a day, and an amount of lorenstat or a pharmaceutically acceptable salt thereof once a day, wherein these amounts taken together are sufficient to treat hypertension in the hypertensive subject.

The present invention provides a trilayer tablet formulation containing telmisartan in an immediate release form, along with two additional antihypertensive agents in immediate or extended release forms, addresses the critical challenges of chemical incompatibility and dissolution interference. This advanced formulation strategy holds promise for improving the management of hypertension through more effective and stable combination therapies.

The invention discloses mytilus coruscus angiotensin converting enzyme inhibitory peptide and application thereof, and belongs to the technical field of biology. The polypeptide with the ACE inhibition effect is prepared and screened from mytilus coruscus by taking the ACE inhibition activity as an index, and comprises VD, LNNP, VQEP, IA and VEEK. Experiments prove that the polypeptide has a blood pressure regulating function, has a protective effect on cell oxidative damage, can relieve damage of oxidative stress to cells, and lays a solid theoretical foundation and technical support for development of antihypertensive drugs based on mytilus coruscus.

[Problem]To provide a technique for lowering blood pressure with the use of a chondroitin sulfate oligosaccharide.[Solution]An antihypertensive drug and an antihypertensive food composition comprising a chondroitin sulfate oligosaccharide as an active ingredient, a method for lowering blood pressure, a method for preventing or improving hypertension, and use of a chondroitin sulfate oligosaccharide for producing an antihypertensive drug. According to the present invention, blood pressure can be lowered or an increase in blood pressure can be inhibited by using the active ingredient by oral administration, namely, a simple and noninvasive form of usage. Thus, the present invention can contribute to the prevention or improvement of hypertensive conditions.

A method for diagnosing or predicting preeclampsia in a pregnant woman or determining whether a pregnant woman is at risk of developing preeclampsia is provided, comprising: a) obtaining at least one (such as two or more) maternal or fetal parameter or factor of the pregnant woman selected from the group comprising: (i) one or more of mean arterial pressure, BMI at sampling, ΔBMI, gestational age, and ΔBMI / GA; (ii) maternal age; (iii) one or more of urinary protein level and ratio of urinary protein level (such as total urinary protein) to urinary creatinine level; (iv) one or more of history of preeclampsia in previous pregnancies and having received antihypertensive medication; and (v) any combination of (i)-(iv), b) determining whether the pregnant woman has misfolded proteins or misfolded protein aggregates in her urine, and c) combining the at least one maternal or fetal parameter or factor obtained in step a) with the level of misfolded proteins or misfolded protein aggregates in the pregnant woman's urine to diagnose or predict preeclampsia or determine the risk of preeclampsia.

The application discloses a preparation method of grifola frondosa protease hydrolysate and a blood pressure reducing polypeptide and application thereof. The sequence of the blood pressure reducing polypeptide is APPLRP, LPPLL, LPPLLL, LPPLPRP, LPPPLLK, LPPRLP, LPPRP or RPPLP, the blood pressure reducing polypeptide is an ACE targeted peptide, and is derived from grifola frondosa protease hydrolysate. The hexapeptide and heptapeptide with the blood pressure reducing function provided by the application can inhibit ACE activity, treat hypertension, are safe and easy to absorb, have no side effects, can be used for preparation or screening of antihypertensive drugs, and have a good application prospect.

1. Name of the designed product: packing box (sandalwood antihypertensive medicinal tea). 2. Use of the designed product: packing for medicinal tea. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

This invention provides an ACE-inhibiting peptide and its application in health foods and antihypertensive drugs, belonging to the field of ACE-inhibiting peptide technology. The ACE-inhibiting peptide is formed by the sequential condensation of Asp-Thr-Phe-Pro-Tyr-Pro-Arg, with the amino acid sequence DTFPYPR. At the same peptide concentration, the ACE-inhibiting effect is further enhanced when this ACE-inhibiting peptide is mixed with other ACE-inhibiting peptides, and it also has a hypotensive effect on hypertensive mice. The ACE-inhibiting peptide of this invention has a small molecular weight and is easily absorbed, making it a potential natural antihypertensive drug or health food. It also opens up new avenues for the development of black beans and the high-value utilization of processing by-products.

The invention provides a life prediction system for atherosclerotic-free heart disease and application of the life prediction system. The prediction system adopts the application of a composition of reagent materials and / or instruments and equipment of individual risk factor information in preparation of the life prediction system for the atherosclerotic-free heart disease: age, gender, waistline, systolic pressure, whether antihypertensive drugs are used in two weeks, total cholesterol, high-density lipoprotein cholesterol, whether smoking is carried out, and whether the life prediction system for the atherosclerotic-free heart disease is used or not. Whether the patient suffers from diabetes mellitus, residence in cities / villages and residence in south / north, atherosclerotic cardiovascular disease family history, smoking cessation intervention conditions, blood pressure reduction intervention conditions and lipid reduction intervention conditions are determined. The system quantifies the benefit of the life span of the non-atherosclerotic heart disease after individuals in Chinese population receive intervention, reveals the importance of earlier and stricter intervention measures on prolonging the life span of the non-atherosclerotic heart disease, and provides a scientific basis and a practical tool for individualized preventive intervention and reasonable allocation of regional medical resources.

Individual interactive and adaptable digital comparative graphs of synchronized and controlled normotensive SBP and DBP created and controlled by individual antihypertensive medications therapies of therapeutic potencies, which decreasing and preventing morbidity and mortality, in the users and wears of the mobile digital blood pressure monitor devices.